Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Small Cell Lung Carcinoma × rovalpituzumab tesirine × Clear all

Phase

Phase 1 4 Phase 3 3 Phase 1/2 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1 Recurrence 1 Neoplasms 1

Interventions

Etoposide 70 Carboplatin 60 Cisplatin 40 Topotecan 26 durvalumab 25 atezolizumab 18 Radiotherapy 18 Irinotecan 18 Paclitaxel 15 Nivolumab 15 apatinib 14 anlotinib 12 Drug Therapy 12 pembrolizumab 9 Platinum 9 toripalimab 8 Bevacizumab 8 Radiosurgery 7 PM 01183 7 Ipilimumab 7 tislelizumab 6 Gemcitabine 6 olaparib 5 amrubicin 5 Temozolomide 5 Sunitinib 5 Pemetrexed 5 Docetaxel 5 Albumin-Bound Paclitaxel 5 irinotecan sucrosofate 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02674568 2021-07-30

TRINITY

AbbVie

Phase 2 Completed

342 enrolled 18 charts

Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡